Novel Urine Test May Predict Bladder Cancer Treatment Response
Researchers have developed a urine test that detects tumor DNA to predict residual bladder cancer after surgery and assess immunotherapy effectiveness.
A newly developed urine test could revolutionize the management of bladder cancer by predicting whether patients will respond to immunotherapy after surgery. The test screens for tumor DNA in urine, enabling physicians to detect residual cancer cells that may remain following tumor removal. This innovation holds significant implications for personalized treatment, potentially sparing patients from ineffective therapies and reducing unnecessary side effects.
Bladder cancer is a common malignancy with high recurrence rates. Standard treatment often involves surgical resection followed by immunotherapy, but not all patients benefit equally. Current monitoring methods, such as cystoscopy and imaging, are invasive, costly, and may miss microscopic residual disease. The new urine-based liquid biopsy offers a non-invasive alternative that could detect minimal residual disease earlier and more accurately.
The test works by identifying genetic mutations and methylation patterns specific to bladder cancer cells in urine samples. In preliminary studies, it successfully distinguished patients with residual cancer from those who were cancer-free after surgery. Moreover, the test showed promise in evaluating whether post-surgical immunotherapy was effectively eliminating cancer cells. If validated in larger trials, this approach could guide clinicians in adjusting treatment regimens in real time.
As immunotherapy advances, companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are developing novel treatments. However, the ability to monitor response non-invasively remains a critical gap. This urine test could fill that gap, providing a tool to optimize the use of these emerging therapies.
The development aligns with broader trends in precision oncology, where biomarkers drive treatment decisions. If widely adopted, the test could reduce reliance on invasive procedures, lower healthcare costs, and improve patient outcomes by enabling timely interventions. It also opens the door to similar approaches for other cancers where tumor DNA sheds into bodily fluids.
While the test is still in research phases, its potential to transform bladder cancer care is substantial. Further studies will need to confirm its sensitivity and specificity in diverse patient populations. Nonetheless, this innovation represents a step toward more personalized, data-driven cancer management.